135 related articles for article (PubMed ID: 38104219)
1. Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation.
Yanagisawa R; Koyama H; Yakushijin K; Uchida N; Jinguji A; Takeda W; Nishida T; Tanaka M; Eto T; Ohigashi H; Ikegame K; Matsuoka KI; Katayama Y; Kanda Y; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Shinohara A; Nakasone H
Bone Marrow Transplant; 2024 Mar; 59(3):325-333. PubMed ID: 38104219
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group.
Yanagisawa R; Tamaki M; Tanoshima R; Misaki Y; Uchida N; Koi S; Tanaka T; Ozawa Y; Matsuo Y; Tanaka M; Ikegame K; Katayama Y; Matsuoka KI; Ara T; Kanda Y; Matsumoto K; Fukuda T; Atsuta Y; Kato M; Nakasone H
Hematol Oncol; 2023 Aug; 41(3):535-545. PubMed ID: 36385399
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
9. Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Kameda K; Harada K; Saburi M; Okinaka K; Shinohara A; Uchida N; Nishijima A; Ozawa Y; Tanaka M; Kuriyama T; Katayama Y; Sawa M; Ikegame K; Kawakita T; Kanda Y; Nakamae H; Ara T; Kimura T; Sato A; Fukuda T; Atsuta Y; Nakasone H
Transplant Cell Ther; 2022 Apr; 28(4):209.e1-209.e9. PubMed ID: 34995815
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
12. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
13. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.
Duncan CN; Majhail NS; Brazauskas R; Wang Z; Cahn JY; Frangoul HA; Hayashi RJ; Hsu JW; Kamble RT; Kasow KA; Khera N; Lazarus HM; Loren AW; Marks DI; Maziarz RT; Mehta P; Myers KC; Norkin M; Pidala JA; Porter DL; Reddy V; Saber W; Savani BN; Schouten HC; Steinberg A; Wall DA; Warwick AB; Wood WA; Yu LC; Jacobsohn DA; Sorror ML
Biol Blood Marrow Transplant; 2015 Jan; 21(1):151-8. PubMed ID: 25316109
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
Parikh CR; Schrier RW; Storer B; Diaconescu R; Sorror ML; Maris MB; Maloney DG; McSweeney P; Storb R; Sandmaier BM
Am J Kidney Dis; 2005 Mar; 45(3):502-9. PubMed ID: 15754272
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes.
DeFilipp Z; Troschel FM; Qualls DA; Li S; Kuklinski MW; Kempner ME; Hochberg E; Chen YB; El-Jawahri A; Fintelmann FJ
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1741-1747. PubMed ID: 29496561
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
Storb R; Gyurkocza B; Storer BE; Sorror ML; Blume K; Niederwieser D; Chauncey TR; Pulsipher MA; Petersen FB; Sahebi F; Agura ED; Hari P; Bruno B; McSweeney PA; Maris MB; Maziarz RT; Langston AA; Bethge W; Vindeløv L; Franke GN; Laport GG; Yeager AM; Hübel K; Deeg HJ; Georges GE; Flowers ME; Martin PJ; Mielcarek M; Woolfrey AE; Maloney DG; Sandmaier BM
J Clin Oncol; 2013 Apr; 31(12):1530-8. PubMed ID: 23478054
[TBL] [Abstract][Full Text] [Related]
19. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
Schneidawind C; Duerr-Stoerzer S; Faul C; Kanz L; Weisel K; Bethge W; Schneidawind D
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28470884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
